Along these lines, EGFR and PI3K/AKT/mTOR pathway inhibitors in clinical use for other tumor types, such as Erlotinib and Afinitor, are under preclinical evaluation in HNSCC cancer. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.